1. AHFS (2007) American hospital formulary service drug information. In McEvoy GK (ed) 8.18.08.20 Nucleoside and nucleotide reverse transcriptase inhibitors, zidovudine. American Society of Health-System Pharmacists, Inc.: Bethesda, MD
2. Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67(2):155–186
3. Avramis VI, Kwock R, Solorzano MM, Gomperts E (1993) Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 6(12):1287–1296
4. Ayers KM, Clive D, Tucker J, Walter E, Hajian G, de Miranda P (1996) Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 32(2):148–158
5. Barbier O, Turgeon D, Girard C et al (2000) 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28(5):497–502